Keywords: Isis Pharma, GlaxoSmithKline, ISI-TTR Rx, USA, FDA, Fas t rack, FAB, Polyneuropathy

Isis Pharma/GlaxoSmithKline's ISIS-TTR Rx gains US fast-track designation

Article | 14 December 2012

Print This

In what has been a busy newsflow few days for USA-based Isis Pharmaceutical (Nasdaq: ISIS), the company said yesterday ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in